Ισραήλ - Εβραϊκά - Ministry of Health

mazor surgical technologies - מומחה - the onyx / amethyst propietary screws are intended for bi-lateral oblique trans-pedicular trans-discal fixation, in order to fixate a single spinal motion segment comprising two adjacent vertebrae

Ισραήλ - Εβραϊκά - Ministry of Health

padagis israel agencies ltd, israel - bupivacaine hydrochloride - תמיסה להזרקה - bupivacaine hydrochloride 5 mg/ml - bupivacaine - bupivacaine - spinal anaesthesia for surgery, e.g. urological and lower limb surgery, lasting 2-3 hours, abdominal surgery lasting 45-60 minutes.

Ισραήλ - Εβραϊκά - Ministry of Health

padagis israel agencies ltd, israel - bupivacaine hydrochloride - תמיסה להזרקה - bupivacaine hydrochloride 5 mg/ml - bupivacaine - bupivacaine - spinal anaesthesia for surgery.

Ισραήλ - Εβραϊκά - Ministry of Health

ביוטיקייר אי גי בעמ - מסיר לק

Ισραήλ - Εβραϊκά - Ministry of Health

medoc ltd, advanced medical systems - מומחה - מישתל מלעורי להרחקה וקיבוע בין שתי חוליות בעמוד השדרה.

Ισραήλ - Εβραϊκά - Ministry of Health

עמוס גזית בע"מ - רופא

Ισραήλ - Εβραϊκά - Ministry of Health

trimaco medical division ltd. - רופא - משתלים ,מכשור, לניתוחים אורטופדיים

Ισραήλ - Εβραϊκά - Ministry of Health

trimaco medical division ltd. - רופא - משתלים ומכשור לניתוחים אורטופדיים, נוירוכירורגיה

Ισραήλ - Εβραϊκά - Ministry of Health

trimaco medical division ltd. - רופא

Ισραήλ - Εβραϊκά - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob